Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVAPORATE: Vascepa for Coronary Atherosclerosis
NCT02926027Phase 4Completed
- Sponsor
- The Lundquist Institute
- Start
- Mar 2017
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in hypertriglyceridemia and Coronary atherosclerosis (CAD) comparing Vascepa with Placebo (2 arms). Primary endpoint: Progression Rates of Low Attenuation Plaque Under Influence of Vascepa as Compared to Placebo at 18 months. Started Mar 2017; status: completed.
02
Drugs
omega-3-acid triglycerides
03
Conditions
hypertriglyceridemiaCoronary atherosclerosis (CAD)
Beyond the preview
Go deeper on NCT02926027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02926027.